-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

SCI-16 DNA Editing: A Primer

Program: Scientific Program
Session: Genome Therapies for Hemoglobinopathies
Saturday, December 5, 2015, 2:00 PM-3:30 PM
Hall D, Level 2 (Orange County Convention Center)
Sunday, December 6, 2015, 9:30 AM-11:00 AM
Valencia A (W415A), Level 4 (Orange County Convention Center)

Prashant Mali, PhD

Bioengineering, University of California, San Diego, La Jolla, CA

RNA-guided Cas9 nucleases based on the prokaryotic CRISPR-Cas systems provide an unprecedented ease in being able to edit the genomes of diverse organisms. As a single unifying factor capable of co-localizing RNA, DNA, and protein, I believe tools and techniques based on Cas9 will grant exquisite control over cellular organization, regulation, and behavior. Here I will describe work on development of the CRISPR-Cas9 targeting methodology, and detail current and prospective genome-engineering methodologies.

Disclosures: No relevant conflicts of interest to declare.

See more of: Genome Therapies for Hemoglobinopathies
See more of: Scientific Program
Previous Presentation | Next Presentation >>